REGN Financial Facts
Cost of goods sold: 29.9MIncome tax benefit: -101.08M
See Full Income Statement
Accounts receivable - other: 1.33B
Total liabilities and stockholders' equity: 6.83B
See Full Balance Sheet
Regeneron Pharmaceuticals, Inc. (REGN) Earnings
|
Expand Research on REGN
Next EPS Date | 5/2/24 | EPS Growth Rate | +0.3% |
---|---|---|---|
Average EPS % Beat Rate | +10.8% | Revenue Growth Rate | +2.2% |
Average % Move 1-Wk after EPS | -0.4% | Normal Earnings Time | Before Open |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
5/2/24 | Q124 | N/A | $10.12 | N/A | N/A | $3.23B | N/A | N/A | N/A | ||
2/2/24 | Q423 | $11.86 | $10.77 | +$1.09 | $3.43B | $3.3B | N/A | Details | |||
11/2/23 | Q323 | N/A | $10.75 | N/A | N/A | $3.23B | N/A | N/A | N/A | ||
8/3/23 | Q223 | $10.24 | $9.85 | +$0.39 | $3.16B | $3.03B | N/A | Details | |||
5/4/23 | Q123 | $10.09 | $9.56 | +$0.53 | $3.16B | $3B | N/A | Details | |||
2/3/23 | Q422 | $12.56 | $10.17 | +$2.39 | $3.41B | $3.13B | N/A | Details | |||
11/3/22 | Q322 | $11.14 | $9.82 | +$1.32 | $2.94B | $2.94B | N/A | Details | |||
8/3/22 | Q222 | $9.77 | $8.60 | +$1.17 | $2.86B | $2.79B | N/A | Details |